GLP-1s, should we all be taking them?

GLP-1 drugs have exploded into the mainstream, but are they truly longevity medicines, or simply powerful tools for treating obesity and metabolic disease?In the first episode Longevity.Technology UNLOCKED, hosts Phil Newman and Dr. Nina Patrick sit down with two of the world’s leading authorities to unpack one of the most important health debates of our time: Should we all be taking GLP-1 agonists?Joining the conversation are Dr. Eric Verdin, CEO of the Buck Institute for Research on Aging, and Professor Jens Juul Holst, the scientist who first discovered the GLP-1 hormone. Together, they explore the science, hype, risks, and real-world implications of drugs like Ozempic, Wegovy, and tirzepatide going far beyond weight loss headlines.From insulin resistance and inflammation to cardiovascular protection, brain health, and the future of preventive medicine, this wide-ranging discussion examines whether GLP-1s could redefine how we think about aging itself. The episode also tackles difficult questions around microdosing, off-label use, muscle loss, access, regulation, and the ethics of medicating lifestyle versus disease.Key Topics: What GLP-1 agonists actually do in the bodyObesity, metabolic syndrome, and lifespanWeight-independent longevity effectsInflammation, cardiovascular and renal protectionBrain health and Alzheimer’s diseaseMicrodosing, personalization, and patient-led experimentationRisks, side effects, and media exaggerationAre GLP-1s the first true preventive longevity drugs?If you care about living longer and healthier and understanding the trade-offs along the way, this is a conversation you don’t want to miss.Subscribe for weekly episodes that dig into longevity science, healthspan optimization, and the technologies shaping our future health.----------Connect with our hosts:Phil Newman: https://qrco.de/bgXpNYDr. Nina Patrick: https://qrco.de/bgXpKn